Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by MrMugsy on Jan 16, 2023 4:15pm

Quiet day ...

It didn't look like a single share was going to trade hands today (on TSX).
Then, all the shares at 69 disappeared at the end of the day ... ~11,500 shares
Someone thinks below 70 is a deal.

All we need is a catalyst my friends.

Someone taking 45,000 shares at maket on the TSX would drive this to 87 cents in seconds.

Been waiting for a catalyst ... anybody got one ?
Comment by Duster340 on Jan 17, 2023 2:27pm
well we never made it to 87, but we did go to 59. picked up a few around 62. no catalyst, not even from management, hoping they have some news for us next earnings report.
Comment by MrMugsy on Jan 18, 2023 10:09am
The next earnings report (late Feb ???) should indicate that cash was around $42.5 MM for the last quarter.  That includes initial payment for the CITA sale. As we understand it - the IBD candidate should have been selected and I can only assume we are waiting for the IP to be accepted at the patent office before they talk about it.  I'm looking for a few things w.r.t. the IBD drug ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities